• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
Home
  • Research
  • Biotech
    • Clinical Data
    • Venture Capital
    • Deals
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Cell & Gene Therapy
    • COVID-19
  • Podcasts
  • Resources
    • Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
Search Icon
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Research
  • Biotech
    • Clinical Data
    • Venture Capital
    • Deals
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Cell & Gene Therapy
    • COVID-19
  • Podcasts
  • Resources
    • Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events

ovarian cancer

Biotech

VBL lays off 35% of staff after failure-induced stock shock

VBL Therapeutics is trimming its workforce by 35% less than two weeks after its lead asset flunked a phase 3 test.
Max Bayer Aug 2, 2022 11:03am

Panic infects VBL investors as therapy fails phase 3 cancer test

Jul 20, 2022 6:30am

Roche pays Repare $125M to join Big Pharma peers in cancer race

Jun 2, 2022 8:27am

Investors fork out $76M for piece of Pheast's cancer therapies

Apr 26, 2022 11:00am

ImmunoGen files ovarian cancer drug with FDA after iffy results

Mar 29, 2022 10:30am

Verastem takes on debt to get RAS tumor program to finish line

Mar 28, 2022 8:30am
Home
  • Connect
    • The Team
    • Advertise
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
  • ©2022 Questex LLC All rights reserved.
  • Terms of use
  • Privacy Policy